Advanced search
Publication Cover
Leukemia & Lymphoma Volume 46, 2005 - Issue 3
Submit an article Journal homepage
168
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma

G Visani Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
B Guiducci Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
F D'Adamo Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
A Mele Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
G Nicolini Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
G Leopardi Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
G Sparaventi Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
S Barulli Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
L Malerba Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
A Isidori Hematology Azienda Ospedale San Salvatore Pesaro Italy
,
M Malagola Hematology Azienda Ospedale San Salvatore Pesaro Italy
&
PP Piccaluga Hematology Azienda Ospedale San Salvatore Pesaro Italy
 show all
Pages 477-479 | Published online: 01 Jul 2009

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Liang Wang & Zhong-Jun Xia. (2013) Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. Leukemia & Lymphoma 54:11, pages 2553-2555.
Read now

Articles from other publishers (9)

Bin Lu, Longfei Shen, Ying Ma, Jia Qi, Yulin Li, Zhihao Wang, Lu Han & Ming Zhong. (2022) Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis. Frontiers in Pharmacology 13.
Crossref
Cheng Zhang, Han Yao, Pei-Yang Kong, Yao Liu, Lei Gao, Li Gao, Ying-Ying Ma, Jun Liu, Xu Tan & Xi Zhang. (2019) Pegylated liposomal doxorubicin for myeloid neoplasms. Anti-Cancer Drugs 30:9, pages 948-952.
Crossref
Giuseppe Visani, Federica Loscocco & Alessandro Isidori. (2014) Nanomedicine strategies for hematological malignancies: what is next?. Nanomedicine 9:15, pages 2415-2428.
Crossref
Yun Fan, Neng-ming Lin, Lü-hong Luo, Luo Fang, Zhi-yu Huang, Hai-feng Yu & Feng-qin Wu. (2011) Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Acta Pharmacologica Sinica 32:3, pages 408-414.
Crossref
Giuseppe VisaniAlessandro Isidori. (2011) Doxorubicin variants for hematological malignancies. Nanomedicine 6:2, pages 303-306.
Crossref
Bo Guo, Hong-Li Zhu, Su-Xia Li, Xue-Chun Lu & Hui Fan. (2011) Individualized Liposomal Doxorubicin-Based Treatment in Elderly Patients with Non-Hodgkin’s Lymphoma. Onkologie 34:4, pages 184-188.
Crossref
Stefano Pulini, Serena Rupoli, Gaia Goteri, Nicola Pimpinelli, Renato Alterini, Alberta Bettacchi, Simonetta Mulattieri, Paola Picardi, Angela Tassetti, Anna Rita Scortechini, Giuseppe Fioritoni & Pietro Leoni. (2009) Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. European Journal of Haematology 82:3, pages 184-193.
Crossref
Lubos Cipak, Lubica Grausova, Eva Miadokova, Ladislav Novotny & Peter Rauko. (2006) Dual activity of triterpenoids: apoptotic versus antidifferentiation effects. Archives of Toxicology 80:7, pages 429-435.
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 23:1, pages 41-48.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.